|
Market Data
Edwards Lifesciences Corporation
Edwards Lifesciences is a global medical technology company specializing in innovative solutions for advanced cardiovascular diseases. The company's core business centers on developing and commercializing transcatheter heart valve technologies, including the Edwards SAPIEN family, which offers minimally invasive aortic valve replacement. Beyond aortic valves, Edwards also provides solutions for mitral and tricuspid valve repair and replacement, utilizing brands like PASCAL PRECISION and Cardioband. Furthermore, the company's portfolio includes surgical structural heart solutions, such as the INSPIRIS and MITRIS RESILIA valves, catering to a broad spectrum of patient needs. Edwards Lifesciences distributes its products through a direct sales force and independent distributors, solidifying its presence in key markets across the United States, Europe, Japan, and internationally.
EW is currently trading at $80.99, giving Edwards Lifesciences Corporation a market cap of 46.75B and a P/E ratio of 43.5. Today's range spans $78.79–$81.69, with shares opening at $78.79 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 50/100.
Over the past year EW has traded between $68.63 and $87.89 - the current price is +18.0% off the 52-week low and -7.9% from the high. 45 analysts cover the stock with a Buy consensus and a mean 12-month target of $96.64 (range $84.00–$110.00), implying upside of +19.3%.
Volatility for EW is compressed - a HOLD signal (59/100) with neutral sentiment (50/100) at $80.99 (in the middle of its 52-week range) in a large-cap Healthcare name (46.75B market cap) is the kind of setup where realized volatility undershoots implied. The current P/E ratio stands at 43.5. Annual range: $68.63–$87.89. That compression typically resolves with a sharp directional move - the question is timing and catalyst, not direction, because HOLD signals at this scale don't stay neutral indefinitely.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $0.73 | - | - |
| Q4'25 | $0.69 | $0.58 | -16.0% |
| Q3'25 | $0.59 | $0.67 | +12.6% |
| Q2'25 | $0.62 | $0.67 | +7.6% |
| Q1'25 | $0.60 | $0.64 | +7.5% |
| Q4'24 | $0.55 | $0.59 | +6.4% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.6B | - | - |
| Q4'25 | $1.6B | $1.6B | +0.2% |
| Q3'25 | - | $1.6B | - |
| Q2'25 | - | $1.5B | - |
| Q1'25 | - | $1.4B | - |
| Q4'24 | - | $1.4B | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).